Immupharma PLC Appointment of Joint Broker (5848B)
20 June 2016 - 4:00PM
UK Regulatory
TIDMIMM
RNS Number : 5848B
Immupharma PLC
20 June 2016
RNS : FOR IMMEDIATE RELEASE 20 JUNE 2016
NORTHLAND CAPITAL APPOINTED AS JOINT BROKER
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, announces the
appointment of Northland Capital Partners as joint broker to the
Company, alongside Panmure Gordon with immediate effect.
-Ends-
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Panmure, Gordon & Co., (NOMAD +44 (0) 20
& Broker) 7886 2500
Fred Walsh, Duncan Monteith, Corporate
Finance
Charles Leigh-Pemberton, Corporate
Broking
Northland Capital Partners Limited
(Joint Broker)
Patrick Claridge, David Hignell,
Corporate Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6631
Notes to Editors
ImmuPharma PLC
ImmuPharma is a pharmaceutical development company listed since
2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on
developing novel medicines with high sales potential in specialist
markets with serious unmet need.
ImmuPharma successfully completed a GBP8.4 million fund raise in
March 2016, comprising a Placing and Subscription together with
confirmation of EIS and VCT qualifying status. Monies raised will
principally be used to complete the pivotal Phase III trial of
Lupuzor(TM). Following the issue of the New Ordinary Shares
ImmuPharma has 121,781,219 ordinary shares of 10 pence each (the
"Ordinary Shares") in issue.
Lupuzor(TM)
Lupuzor(TM) (also referred to as Forigerimod, or P140) is
ImmuPharma's lead compound and a potential treatment for lupus (or
Systemic Lupus Erythematosus), a chronic, potentially
life-threatening auto-immune disease. Lupuzor(TM) has a novel
mechanism of action aimed at modulating the body's immune system so
that it does not attack healthy cells, and avoids causing adverse
side effects. It has the potential to halt the progression of the
disease in a substantial proportion of patients.
Lupuzor(TM) has been granted Fast Track status by the US FDA and
approval to start Phase III under Special Protocol Assessment
(SPA). This SPA was subsequently amended due to its strong safety
and efficacy profile to allow for a reduced number of patients in
the pivotal Phase III trial thereby reducing the projected cost and
time of development considerably.
The pivotal Phase III clinical study is entitled "A 52-Week,
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study
to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101
Plus Standard of Care in Patients With Systemic Lupus
Erythematosus". It is a pivotal study designed to demonstrate the
safety and efficacy of IPP-201101 and as a last step prior to the
filing of the drug for approval with the US Food & Drug
Administration ("FDA") and the European Medicines Agency ("EMA").
For more information please visit:
www.ClinicalTrials.gov/lupuzor
Commercial Opportunity
There are an estimated five million people globally suffering
from Lupus, with approximately 1.5 million patients in the US,
Europe and Japan (Source: Lupus Foundation of America). Current
'standard of care' treatments, including steroids and
immunosuppressants, can potentially have either serious side
effects for patients or limited effectiveness, with over 60% of
patients not adequately treated. GSK's Benlysta is the first Lupus
drug approved in over 50 years and paves the path to market for
Lupuzor(TM). Based on conservative estimates, and taking into
account that Benlysta is priced currently at approximately $35,000
per patient per year, Lupuzor(TM) would be entering a market with
the potential for multi-billion dollar sales. For more information
on Lupuzor(TM) please visit: www.lupuzor.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPUBUURNWANAAR
(END) Dow Jones Newswires
June 20, 2016 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024